Cargando…

First person – Ling-shiang Chuang

First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms (DMM), helping early-career researchers promote themselves alongside their papers. Ling-shiang (Felix) Chuang is first author on ‘Zebrafish modeling of intestinal injur...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737957/
http://dx.doi.org/10.1242/dmm.041624
_version_ 1783450750574133248
collection PubMed
description First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms (DMM), helping early-career researchers promote themselves alongside their papers. Ling-shiang (Felix) Chuang is first author on ‘Zebrafish modeling of intestinal injury, bacterial exposures and medications defines epithelial in vivo responses relevant to human inflammatory bowel disease’, published in DMM. Ling-shiang is an instructor in the lab of Judy Cho at Icahn School of Medicine at Mount Sinai, New York, USA, investigating how to establish human genetic-driven personalized drug treatments for inflammatory bowel disease (IBD) by using zebrafish as a screening model.
format Online
Article
Text
id pubmed-6737957
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Company of Biologists Ltd
record_format MEDLINE/PubMed
spelling pubmed-67379572019-09-12 First person – Ling-shiang Chuang Dis Model Mech First Person First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms (DMM), helping early-career researchers promote themselves alongside their papers. Ling-shiang (Felix) Chuang is first author on ‘Zebrafish modeling of intestinal injury, bacterial exposures and medications defines epithelial in vivo responses relevant to human inflammatory bowel disease’, published in DMM. Ling-shiang is an instructor in the lab of Judy Cho at Icahn School of Medicine at Mount Sinai, New York, USA, investigating how to establish human genetic-driven personalized drug treatments for inflammatory bowel disease (IBD) by using zebrafish as a screening model. The Company of Biologists Ltd 2019-08-01 2019-08-13 /pmc/articles/PMC6737957/ http://dx.doi.org/10.1242/dmm.041624 Text en © 2019. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/4.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle First Person
First person – Ling-shiang Chuang
title First person – Ling-shiang Chuang
title_full First person – Ling-shiang Chuang
title_fullStr First person – Ling-shiang Chuang
title_full_unstemmed First person – Ling-shiang Chuang
title_short First person – Ling-shiang Chuang
title_sort first person – ling-shiang chuang
topic First Person
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737957/
http://dx.doi.org/10.1242/dmm.041624